{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:41:13Z","timestamp":1785904873076,"version":"3.56.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12035-021-02437-3","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T20:03:23Z","timestamp":1622750603000},"page":"4520-4534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Carbonic Anhydrase Inhibitor E7070 Sensitizes Glioblastoma Cells to Radio- and Chemotherapy and Reduces Tumor Growth"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2462-8535","authenticated-orcid":false,"given":"Silvia A.","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano S.","family":"Viapiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto F.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan S.","family":"Nandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Pezuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas T.","family":"Bidinotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veridiana K.","family":"Suazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Neder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos G.","family":"Carlotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline P.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Gonzaga","family":"Tone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Scrideli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"2437_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466","journal-title":"Lancet Oncol"},{"key":"2437_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, Deimling A, Figarella-Branger D, Cavenee WB et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803\u2013820","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2437_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1586\/era.12.37","volume":"12","author":"TCA Johannessen","year":"2012","unstructured":"Johannessen TCA, Bjerkvig R (2012) Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 12(5):635\u2013642","journal-title":"Expert Rev Anticancer Ther"},{"key":"2437_CR4","first-page":"17","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S (2021) Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist 4:17\u201343","journal-title":"Cancer Drug Resist"},{"issue":"Suppl 4","key":"2437_CR5","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1053\/j.seminoncol.2011.09.005","volume":"38","author":"S Kesari","year":"2011","unstructured":"Kesari S (2011) Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol 38(Suppl 4):S2-10","journal-title":"Semin Oncol"},{"key":"2437_CR6","doi-asserted-by":"crossref","unstructured":"Soda Y, Myskiw C, Rommel A, Verma IM (2013) Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) 91(4):439\u2013448","DOI":"10.1007\/s00109-013-1019-z"},{"key":"2437_CR7","doi-asserted-by":"crossref","unstructured":"Ho IAW, Shim WSN (2017) Contribution of the microenvironmental niche to glioblastoma heterogeneity. Biomed Res Int 2017:9634172","DOI":"10.1155\/2017\/9634172"},{"key":"2437_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"AE Nejad","year":"2021","unstructured":"Nejad AE, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarina M et al (2021) The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int 21:62","journal-title":"Cancer Cell Int"},{"key":"2437_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","volume":"27","author":"CT Supuran","year":"2018","unstructured":"Supuran CT (2018) Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 27:963\u2013970","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"2437_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/cancers12071723","volume":"12","author":"J Haapasalo","year":"2020","unstructured":"Haapasalo J, Nordfors K, Haapasalo H, Parkkila S (2020) The expression of carbonic anhydrases II, IX and XII in brain tumors. Cancers (Basel) 12(7):1723","journal-title":"Cancers (Basel)"},{"key":"2437_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00005-012-0203-0","volume":"61","author":"S Agnihotri","year":"2013","unstructured":"Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT et al (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp 61:25\u201341","journal-title":"Arch Immunol Ther Exp"},{"key":"2437_CR12","doi-asserted-by":"crossref","unstructured":"Muz B, de la Puente P, Azab F, Azab AK (2015) The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) 11(3):83\u201392","DOI":"10.2147\/HP.S93413"},{"key":"2437_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.mam.2017.01.009","volume":"55","author":"D Uribe","year":"2017","unstructured":"Uribe D, Torres \u00c1, Rocha JD, Niechi I, Oyarz\u00fan C, Sobrevia L et al (2017) Multidrug resistance in glioblastoma stem-like cells: role of the hypoxic microenvironment and adenosine signaling. Mol Aspects Med 55:140\u2013151","journal-title":"Mol Aspects Med"},{"issue":"10","key":"2437_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/metabo10100412","volume":"10","author":"A Angeli","year":"2020","unstructured":"Angeli A, Carta F, Nocentini A, Winum J-Y, Zaluboskis R, Akdemir A et al (2020) Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites 10(10):412","journal-title":"Metabolites"},{"issue":"1","key":"2437_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z, Liu S et al (2021) Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res 40(1):24","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2437_CR16","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.3390\/ijms22063171","volume":"22","author":"HM Becker","year":"2021","unstructured":"Becker HM, Deitmer JW (2021) Proton transport in cancer cells: the role of carbonic anhydrases. Int J Mol Sci 22(6):3171","journal-title":"Int J Mol Sci"},{"key":"2437_CR17","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.1038\/onc.2017.219","volume":"36","author":"M Swayampakula","year":"2017","unstructured":"Swayampakula M, McDonald PC, Vallejo M, Coyaud E, Chafe SC, Westerback A et al (2017) The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia\/MMP14-mediated invasion. Oncogene 36:6244\u20136261","journal-title":"Oncogene"},{"issue":"1\u20132","key":"2437_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","volume":"38","author":"S Pastorekova","year":"2019","unstructured":"Pastorekova S, Gillies RJ (2019) The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev 38(1\u20132):65\u201377","journal-title":"Cancer Metastasis Rev"},{"key":"2437_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fphys.2013.00400","volume":"4","author":"O Sedlakova","year":"2014","unstructured":"Sedlakova O (2014) Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front Physiol 4:400","journal-title":"Front Physiol"},{"key":"2437_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2174\/138161208783877893","volume":"14","author":"J Pastorek","year":"2008","unstructured":"Pastorek J, Pastorekova S, Zatovicova M (2008) Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 14:685\u2013698","journal-title":"Curr Pharm Des"},{"key":"2437_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1215\/15228517-2007-065","volume":"10","author":"J Haapasalo","year":"2008","unstructured":"Haapasalo J, Hilvo M, Nordfors K et al (2008) Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro Oncol 10:131\u2013138","journal-title":"Neuro Oncol"},{"key":"2437_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2174\/138161208783877884","volume":"14","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases\u2013an overview. Curr Pharm Des 14:603\u2013614","journal-title":"Curr Pharm Des"},{"key":"2437_CR23","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.2174\/138161210793429788","volume":"16","author":"HM Said","year":"2010","unstructured":"Said HM, Supuran CT, Hageman C, Staab A, Polat B, Katzer A et al (2010) Modulation of carbonic anhydrase 9 (CA9) in human brain cancer. Curr Pharm Des 16:3288\u20133299","journal-title":"Curr Pharm Des"},{"key":"2437_CR24","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","volume":"71","author":"Y Lou","year":"2011","unstructured":"Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund AA, Kyle A et al (2011) Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 71:3364\u20133376","journal-title":"Cancer Res"},{"issue":"3","key":"2437_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-008-9579-4","volume":"88","author":"CA Scrideli","year":"2008","unstructured":"Scrideli CA, Carlotti CG, Okamoto OK, Andrade VS, Cortez MAA, Motta FJN et al (2008) Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol 88(3):281\u2013291","journal-title":"J Neurooncol"},{"key":"2437_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00383-015-3831-8","volume":"32","author":"HM Ameis","year":"2016","unstructured":"Ameis HM, Drenckhan A, Freytag M, Izbicki JR, Supuran CT, Reinshagen K et al (2016) Influence of hypoxia-dependent factors on the progression of neuroblastoma. Pediatr Surg Int 32:187\u2013192","journal-title":"Pediatr Surg Int"},{"key":"2437_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1053\/j.gastro.2019.05.004","volume":"157","author":"PC McDonald","year":"2019","unstructured":"McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula GV, Nemirosvky O et al (2019) Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia. Gastroenterology 157:823\u2013837","journal-title":"Gastroenterology"},{"key":"2437_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1600-0714.2012.01147.x","volume":"41","author":"M P\u00e9rez-Say\u00e1ns","year":"2012","unstructured":"P\u00e9rez-Say\u00e1ns M, Su\u00e1rez-Pe\u00f1aranda JM, Pilar G-D, Supuran CT, Pastorekova S, Barros-Angueira F et al (2012) Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients. J Oral Pathol Med 41:667\u2013674","journal-title":"J Oral Pathol Med"},{"key":"2437_CR29","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ejcb.2010.03.004","volume":"89","author":"M-J Hsieh","year":"2010","unstructured":"Hsieh M-J, Chen K-S, Chiou H-L, Hsieh Y-S (2010) Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway. Eur J Cell Biol 89:598\u2013606","journal-title":"Eur J Cell Biol"},{"key":"2437_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.lungcan.2013.07.005","volume":"82","author":"M Ilie","year":"2013","unstructured":"Ilie M, Hofman V, Zangari J, Chiche J, Mouroux J, Mazure NM et al (2013) Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients. Lung Cancer 82:16\u201323","journal-title":"Lung Cancer"},{"key":"2437_CR31","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.bmcl.2005.02.091","volume":"15","author":"JY Winum","year":"2005","unstructured":"Winum JY, Innocenti A, Nasr J, Montero J, Scozzafava A, Vullo D, Supuran C (2005) Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic\/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamides - a new zinc-binding function in the design of inhibitors. Bioorganic Med Chem Lett 15:2353\u20132358","journal-title":"Bioorganic Med Chem Lett"},{"key":"2437_CR32","doi-asserted-by":"publisher","first-page":"6776","DOI":"10.18632\/oncotarget.2882","volume":"6","author":"J Kopecka","year":"2015","unstructured":"Kopecka J, Campia I, Jacobs A, Frei AP, Ghigo D, Wollscheid B et al (2015) Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget 6:6776\u20136793","journal-title":"Oncotarget"},{"key":"2437_CR33","doi-asserted-by":"crossref","unstructured":"Supuran CT (2016) How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 31:345\u2013360","DOI":"10.3109\/14756366.2015.1122001"},{"key":"2437_CR34","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1016\/j.bmc.2013.03.068","volume":"21","author":"HM Said","year":"2013","unstructured":"Said HM, Hagemann C, Carta F, Katzer A, Polat B, Staab A et al (2013) Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma. Bioorg Med Chem 21:3949\u20133957","journal-title":"Bioorg Med Chem"},{"key":"2437_CR35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/COC.0000000000000691","volume":"43","author":"PC McDonald","year":"2020","unstructured":"McDonald PC, Chia S, Bedard PL, Chu Q, Lyle M, Tang L et al (2020) A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol Cancer Clin Trials 43:484\u2013490","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"2437_CR36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1349-7006.2005.00109.x","volume":"96","author":"Y Yamada","year":"2005","unstructured":"Yamada Y, Yamamoto N, Shimoyama T, Horiike A, Fujisaka Y, Takayama K et al (2005) Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci 96:721\u2013728","journal-title":"Cancer Sci"},{"key":"2437_CR37","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1021\/jm800121c","volume":"51","author":"K D\u2019Ambrosio","year":"2008","unstructured":"D\u2019Ambrosio K, Vitale RM, Dogn\u00e9 JM, Masereel B, Innocenti A, Scozzafava A et al (2008) Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. J Med Chem 51:3230\u20133237","journal-title":"J Med Chem"},{"key":"2437_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bmcl.2003.09.062","volume":"14","author":"F Abbate","year":"2004","unstructured":"Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT (2004) Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorganic Med Chem Lett 14:217\u2013223","journal-title":"Bioorganic Med Chem Lett"},{"key":"2437_CR39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7:168\u2013181","journal-title":"Nat Rev Drug Discov"},{"key":"2437_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1023\/A:1010608317361","volume":"19","author":"K Fukuoka","year":"2001","unstructured":"Fukuoka K, Usuda J, Iwamoto Y, Fukumoto H, Nakamura T, Yoneda T et al (2001) Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs 19:219\u2013227","journal-title":"Invest New Drugs"},{"key":"2437_CR41","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"N a P Franken","year":"2006","unstructured":"Franken N a P, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315\u20132319","journal-title":"Nat Protoc"},{"key":"2437_CR42","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/sj.bjc.6604083","volume":"97","author":"Y Tao","year":"2007","unstructured":"Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, Bourhis J et al (2007) Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 97:1664\u20131672","journal-title":"Br J Cancer"},{"key":"2437_CR43","doi-asserted-by":"crossref","unstructured":"Agudelo-Garcia PA, Jesus JK De, Williams SP, Nowicki MO, Chiocca EA, Liyanarachchi S et al (2011) Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. Neoplasia 13:831\u2013840","DOI":"10.1593\/neo.11612"},{"key":"2437_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2199-10-17","volume":"10","author":"V Valente","year":"2009","unstructured":"Valente V, Teixeira SA, Neder L, Okamoto OK, Oba-Shinjo SM, Marie SKN et al (2009) Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol Biol 10:17","journal-title":"BMC Mol Biol"},{"key":"2437_CR45","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/S0959-8049(01)00275-1","volume":"37","author":"Y Ozawa","year":"2001","unstructured":"Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N et al (2001) E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 37:2275\u20132282","journal-title":"Eur J Cancer"},{"key":"2437_CR46","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1158\/1541-7786.MCR-09-0207","volume":"7","author":"B Hu","year":"2009","unstructured":"Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS (2009) Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 7:1756\u20131770","journal-title":"Mol Cancer Res"},{"key":"2437_CR47","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/bioinformatics\/btv677","volume":"32","author":"YW Wan","year":"2016","unstructured":"Wan YW, Allen GI, Liu Z (2016) TCGA2STAT: simple TCGA data access for integrated statistical analysis in R. Bioinformatics 32:952\u2013954","journal-title":"Bioinformatics"},{"key":"2437_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/0008-5472.CAN-08-2470","volume":"69","author":"J Chiche","year":"2009","unstructured":"Chiche J, Ilc K, Laferri\u00e8re J, Trottier E, Dayan F, Mazure NM et al (2009) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69:358\u2013368","journal-title":"Cancer Res"},{"key":"2437_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/9781681083339116050004","volume":"5","author":"MY Mboge","year":"2016","unstructured":"Mboge MY, McKenna RC, Frost S (2016) Advances in anti-cancer drug development targeting carbonic anhydrase IX and XII. Topics in Anti-Cancer Research 5:3\u201342","journal-title":"Topics in Anti-Cancer Research"},{"issue":"7","key":"2437_CR50","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/13543776.2019.1629419","volume":"29","author":"S Zamanova","year":"2019","unstructured":"Zamanova S, Shabana AM, Mondal UK, Ilies MA (2019) Carbonic anhydrases as disease markers. Expert Opin Ther Pat 29(7):509\u2013533","journal-title":"Expert Opin Ther Pat"},{"key":"2437_CR51","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3554","volume":"10","author":"D Neri","year":"2011","unstructured":"Neri D, Supuran CT (2011) Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 10:767\u2013777","journal-title":"Nat Rev Drug Discov"},{"key":"2437_CR52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jcp.22400","volume":"226","author":"SK Parks","year":"2011","unstructured":"Parks SK, Chiche J, Pouyssegur J (2011) pH control mechanisms of tumor survival and growth. J Cell Physiol 226:299\u2013308","journal-title":"J Cell Physiol"},{"key":"2437_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/metabo8010013","volume":"8","author":"C Ward","year":"2018","unstructured":"Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ et al (2018) Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness. Metabolites 8:1\u201313","journal-title":"Metabolites"},{"key":"2437_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ando.2013.02.004","volume":"74","author":"J Chiche","year":"2013","unstructured":"Chiche J, Ricci JE, Pouyss\u00e9gur J (2013) Tumor hypoxia and metabolism - towards novel anticancer approaches. Ann Endocrinol 74:111\u2013114","journal-title":"Ann Endocrinol"},{"key":"2437_CR55","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1158\/0008-5472.CAN-13-1110","volume":"73","author":"G Gondi","year":"2013","unstructured":"Gondi G, Mysliwietz J, Hulikova A, Jen JP, Swietach P, Kremmer E, Zeidler R (2013) Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res 73:6494\u20136503","journal-title":"Cancer Res"},{"key":"2437_CR56","doi-asserted-by":"crossref","unstructured":"Conklin KA (2004) Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3(4):294\u2013300","DOI":"10.1177\/1534735404270335"},{"key":"2437_CR57","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2174\/0929867013371996","volume":"8","author":"T Owa","year":"2001","unstructured":"Owa T, Yoshino H, Yoshimatsu K, Nagasu T (2001) Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 8:1487\u20131503","journal-title":"Curr Med Chem"},{"key":"2437_CR58","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0960-894X(02)00376-1","volume":"12","author":"T Owa","year":"2002","unstructured":"Owa T, Yoshino H, Okauchi T, Okabe T, Ozawa Y, Hata Sugi N et al (2002) Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents. Bioorg Med Chem Lett 12:2097\u20132100","journal-title":"Bioorg Med Chem Lett"},{"key":"2437_CR59","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00280-012-1844-8","volume":"69","author":"Y Ozawa","year":"2012","unstructured":"Ozawa Y, Kusano K, Owa T, Yokoi A, Asada A, Yoshimatsu K (2012) Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment. Cancer Chemother Pharmacol 69:1353\u20131362","journal-title":"Cancer Chemother Pharmacol"},{"key":"2437_CR60","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/CMR.0b013e3282ef4189","volume":"17","author":"M Baur","year":"2007","unstructured":"Baur M, Gneist M, Owa T, Dittrich C (2007) Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070). Melanoma Res 17:329\u2013331","journal-title":"Melanoma Res"},{"key":"2437_CR61","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-06-0249","volume":"13","author":"DC Talbot","year":"2007","unstructured":"Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS et al (2007) A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 13:1816\u20131822","journal-title":"Clin Cancer Res"},{"key":"2437_CR62","doi-asserted-by":"publisher","first-page":"6905","DOI":"10.1021\/jm200892s","volume":"54","author":"JC Morris","year":"2011","unstructured":"Morris JC, Chiche J, Grellier C, Lopez M, Bornaghi LF, Maresca A et al (2011) Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem 54:6905\u20136918","journal-title":"J Med Chem"},{"key":"2437_CR63","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1073\/pnas.040554897","volume":"97","author":"S Parkkila","year":"2000","unstructured":"Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S et al (2000) Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci U S A 97:2220\u20132224","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2437_CR64","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ctrv.2012.08.004","volume":"39","author":"C Ward","year":"2013","unstructured":"Ward C, Langdon SP, Mullen P, Harris A, Harrison D, Supuran C, Kunkler I (2013) New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev 39:171\u2013179","journal-title":"Cancer Treat Rev"},{"key":"2437_CR65","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.bmc.2012.09.062","volume":"21","author":"R Gieling","year":"2013","unstructured":"Gieling R, Williams K (2013) Carbonic anhydrase IX as a target for metastatic disease. Bioorg Med Chem 21:1470\u20131476","journal-title":"Bioorg Med Chem"},{"issue":"24","key":"2437_CR66","doi-asserted-by":"publisher","first-page":"e92928","DOI":"10.1172\/jci.insight.92928","volume":"2","author":"NH Boyd","year":"2017","unstructured":"Boyd NH, Walker K, Fried J, Hackney JR, McDonald GAB, Spina R et al (2017) Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI insight 2(24):e92928","journal-title":"JCI insight"},{"key":"2437_CR67","doi-asserted-by":"crossref","unstructured":"Vartanian A, Singh SK, Agnihotri S, Jalali S, Burrell K, Aldape KD et al (2014) GBM\u2019s multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro Oncol 16(9):1167\u20131175","DOI":"10.1093\/neuonc\/nou035"},{"key":"2437_CR68","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.bmc.2014.01.031","volume":"22","author":"KK Sethi","year":"2014","unstructured":"Sethi KK, Verma SM, Tan\u00e7 M, Purper G, Calafato G, Carta F, Supuran CT (2014) Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties. Bioorganic Med Chem 22:1586\u20131595","journal-title":"Bioorganic Med Chem"},{"key":"2437_CR69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.radonc.2013.06.018","volume":"108","author":"L Dubois","year":"2013","unstructured":"Dubois L, Peeters SGJA, Van Kuijk SJA, Yaromina A, Lieuwes NG, Saraya R et al (2013) Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother Oncol 108:523\u2013528","journal-title":"Radiother Oncol"},{"key":"2437_CR70","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14756366.2018.1532419","volume":"34","author":"E Andreucci","year":"2019","unstructured":"Andreucci E, Ruzzolini J, Peppicelli S, Bianchini AL, Carta F, Supuran CT, Calorini L (2019) The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzyme Inhib Med Chem 34:117\u2013123","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2437_CR71","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-11-1877","volume":"18","author":"A McIntyre","year":"2012","unstructured":"McIntyre A, Patiar S, Wigfield S, Ledaki I, Turley H, Leek R et al (2012) Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 18:3100\u20133111","journal-title":"Clin Cancer Res"},{"key":"2437_CR72","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","volume":"19","author":"H Ohgaki","year":"2013","unstructured":"Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764\u2013772","journal-title":"Clin Cancer Res"},{"key":"2437_CR73","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","volume":"20","author":"R Stupp","year":"2002","unstructured":"Stupp R, Dietrich PY, Kraljevic SO, Pica A, Maillard I, Maeder P et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375\u20131382","journal-title":"J Clin Oncol"},{"key":"2437_CR74","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003","journal-title":"N Engl J Med"},{"key":"2437_CR75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5732\/cjc.012.10236","volume":"33","author":"ZK Qiu","year":"2014","unstructured":"Qiu ZK, Shen D, Chen YS, Yang QY, Guo CC, Feng BH et al (2014) Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer 33:115\u2013122","journal-title":"Chin J Cancer"},{"issue":"2","key":"2437_CR76","doi-asserted-by":"publisher","first-page":"665","DOI":"10.7150\/thno.41692","volume":"11","author":"NH Boyd","year":"2021","unstructured":"Boyd NH, Tran AN, Bernstock JD, Etminam T, Jones AB, Gillespie GY et al (2021) Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics 11(2):665\u2013683","journal-title":"Theranostics"},{"key":"2437_CR77","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1215\/S1152851704000821","volume":"7","author":"C Giannini","year":"2005","unstructured":"Giannini C (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164\u2013176","journal-title":"Neuro Oncol"},{"key":"2437_CR78","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/2193-1801-3-120","volume":"3","author":"C Gkogkou","year":"2014","unstructured":"Gkogkou C, Frangia K, Saif MW, Trigidou R, Syrigos K (2014) Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review. Springerplus 3:120","journal-title":"Springerplus"},{"key":"2437_CR79","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/sj.bjc.6603606","volume":"96","author":"C Dittrich","year":"2007","unstructured":"Dittrich C, Zandvliet a S, Gneist M, Huitema AD, King AA, Wanders J (2007) A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br J Cancer 96:559\u2013566","journal-title":"Br J Cancer"},{"key":"2437_CR80","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1002\/cncr.31398","volume":"124","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N et al (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758\u20132765","journal-title":"Cancer"},{"key":"2437_CR81","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1748-717X-7-25","volume":"7","author":"WJ Kil","year":"2012","unstructured":"Kil WJ, Tofilon PJ, Camphausen K (2012) Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol 7:25","journal-title":"Radiat Oncol"},{"key":"2437_CR82","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4161\/cc.27818","volume":"13","author":"S Yano","year":"2014","unstructured":"Yano S, Miwa S, Mii S, Hiroshima Y, Uehara F, Yamamoto M et al (2014) Invading cancer cells are predominantly in G0\/G1 resulting in chemoresistance demonstrated by real-time FUCCI imaging. Cell Cycle 13:953\u2013960","journal-title":"Cell Cycle"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02437-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-021-02437-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02437-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T05:25:20Z","timestamp":1725168320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-021-02437-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":82,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1007\/s12035-021-02437-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"22 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving animals were performed in accordance Institutional Commission of Ethics in Animal Research (CETEA) at the Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo (S\u00e3o Paulo, SP, Brazil) and Institutional Animal Care and Use Committees at Harvard Medical School\/Brigham and Women's Hospital (HMA-IACUC\u2014Boston, MA, USA). The study was carried out in compliance with the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All authors consent to the publication of current data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}